BRS201
Phase 2Small molecule
BRS201 is one of 14 small molecule programs targeting Colitis. It is currently in Phase 2.
1
Indications
3
Total Trials
3
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Colitis
#DrugCompanyPhaseTrials
1Simponi
Johnson & JohnsonApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Imuran
LLegacy Health System
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Remicade
Johnson & JohnsonPhase 3
Medrol
PfizerPhase 3
Entyvio
TakedaPhase 2
Lialda
TakedaPhase 2
Rayos
RRoxane Laboratories
Phase 2
Actigall
AbbViePhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colitis1 trial
Study of Novel Therapeutics for Acute Remedy of Colitis
Recruiting·—·Phase 2·NCT06420492·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BRS201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBrigham and Women's Hospital